Search alternatives:
significant factor » significant factors (Expand Search)
better decrease » greater decrease (Expand Search), between decreased (Expand Search)
factor decrease » factors increases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
Showing 6,041 - 6,060 results of 6,174 for search '(( significantly ((better decrease) OR (teer decrease)) ) OR ( significant factor decrease ))', query time: 0.53s Refine Results
  1. 6041
    Table 4_Comparative proteomic analysis of the telogen-to-anagen transition in cashmere goat secondary hair follicles.csv

    Table 4_Comparative proteomic analysis of the telogen-to-anagen transition in cashmere goat secondary hair follicles.csv by Xiaoyu Han (550622)

    Published 2025
    “…Anagen-phase SHFs exhibit significantly increased volume, deeper dermal penetration, and active cell proliferation. …”
    Save to List
    Saved in:
  2. 6042
    Table 1_Comparative proteomic analysis of the telogen-to-anagen transition in cashmere goat secondary hair follicles.pdf

    Table 1_Comparative proteomic analysis of the telogen-to-anagen transition in cashmere goat secondary hair follicles.pdf by Xiaoyu Han (550622)

    Published 2025
    “…Anagen-phase SHFs exhibit significantly increased volume, deeper dermal penetration, and active cell proliferation. …”
    Save to List
    Saved in:
  3. 6043
    Table 2_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv

    Table 2_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv by Siying Wei (5990276)

    Published 2025
    “…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”
    Save to List
    Saved in:
  4. 6044
    Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.tif

    Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  5. 6045
    Table 1_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv

    Table 1_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv by Siying Wei (5990276)

    Published 2025
    “…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”
    Save to List
    Saved in:
  6. 6046
    Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.tif

    Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  7. 6047
    Image 1_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.tiff

    Image 1_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.tiff by Siying Wei (5990276)

    Published 2025
    “…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”
    Save to List
    Saved in:
  8. 6048
    Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.doc

    Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  9. 6049
    Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.tif

    Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  10. 6050
    Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.tif

    Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  11. 6051
    Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.tif

    Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  12. 6052
    Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.doc

    Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  13. 6053
    Table 3_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv

    Table 3_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv by Siying Wei (5990276)

    Published 2025
    “…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”
    Save to List
    Saved in:
  14. 6054
    Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.doc

    Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  15. 6055
    Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.doc

    Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  16. 6056
    Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.docx

    Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  17. 6057
    Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.tif

    Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  18. 6058
    Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.doc

    Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  19. 6059
    Table 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.doc

    Table 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:
  20. 6060
    Image 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.tif

    Image 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”
    Save to List
    Saved in:

Search Tools: